Targets › IL6R
11 programs from 9 companies in 73 trials: 32 Phase 2, 26 Phase 3, 11 Phase 1, 4 Phase 4; Immunology, Neurology, Oncology; next expected readout Nov 2026.
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. (UniProt, P08887)
Open in Phaseline: the race on IL6R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Satralizumab IL6Ralpha/GP130 antagonist | IL6R, IL6ST | Phase 3 | NMDAR Autoimmune Encephalitis; Neuromyelitis Optica Spectrum Disorder; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD); Duchenne Muscular Dystrophy … | Nov 2026 |
| Johnson & Johnson (Janssen) | Icotrokinra (JNJ-77242113) IL-6 receptor antagonist | IL6R | Phase 3 | Arthritis, Psoriatic; Plaque Psoriasis; Colitis, Ulcerative; Crohn Disease | Feb 2027 |
| Kodiak Sciences | KSI-101 IL-6 receptor antagonist (IL-6R-Fc fusion protein) | IL6R | Phase 3 | Macular Edema Secondary to Inflammation | Feb 2027 |
| Beijing VDJBio | VDJ001 IL-6 receptor antagonist monoclonal antibody | IL6R | Phase 3 | Anti IL-6R | Jun 2027 |
| Biocad | Levilimab Interleukin-6 receptor alpha subunit inhibitor | IL6R | Phase 3 | Rheumatoid Arthritis | Dec 2027 |
| Sanofi | Sarilumab (SAR153191) Interleukin-6 receptor alpha subunit antagonist | IL6R | Phase 3 | Polymyalgia Rheumatica; Juvenile Idiopathic Arthritis; Rheumatoid Arthritis; Melanoma … | Mar 2028 |
| R-Pharm | RPH-104 IL-6 receptor antagonist | IL6R | Phase 3 | Idiopathic Recurrent Pericarditis; Familial Mediterranean Fever | Dec 2028 |
| Beijing VDJBio | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection anti-IL-6 receptor monoclonal antibody | IL6R | Phase 2 | Idiopathic Multicentric Castleman's Disease | – |
| Roche | Tocilizumab Interleukin-6 receptor alpha subunit inhibitor | IL6R | Phase 1 | Advanced Liver Cancers; Takayasu Arteritis; Primary Cutaneous Amyloidosis; Giant Cell Arteritis … | Jul 2027 |
| University of Florida | tocilizumab-aazg (TYENNE) IL-6 receptor antagonist (anti-IL-6R monoclonal antibody) | IL6R | Phase 1 | Aneurysmal Subarachnoid Hemorrhage | Jul 2028 |
| Innovent Biologics (Suzhou) | IBI3011 Anti-IL-RAP humanised monoclonal antibody | IL6R | Phase 1 | Acute Gout Flare | – |
Plaque Psoriasis (5) Rheumatoid Arthritis (2) Arthritis, Psoriatic (2) Melanoma (2) Takayasu Arteritis (2) Giant Cell Arteritis (2) Sickle Cell Disease (2) Familial Mediterranean Fever (2) Macular Edema Secondary to Inflammation (2) Idiopathic Multicentric Castleman's Disease (1) Colitis, Ulcerative (1) Crohn Disease (1)
antibody (6), protein or peptide (2), small molecule (2), mixed (1)
Beijing VDJBio (2) Roche (2) Biocad (1) Johnson & Johnson (Janssen) (1) Innovent Biologics (Suzhou) (1) Sanofi (1) R-Pharm (1) Kodiak Sciences (1) University of Florida (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.